Claims for Patent: 9,867,820

Summary for Patent: 9,867,820

Title:	Role of N-2-hydroxy-ethyl-piperazine-N\'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury
Abstract:	Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
Inventor(s):	Danhof; Ivan E. (Grand Prairie, TX)
Assignee:	Bespoke Bioscience, LLC (Dallas, TX)
Application Number:	14/481,582
Patent Claims:	1. A method of treating neurological impairment caused by diseases that cause demyelination in a human subject comprising the steps of: identifying a human subject in need for treatment against the neurological impairment caused by the disease that causes demyelination selected from the group consisting of transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukodystrophy, Guillain-Barre syndrome Charcot-Marie-Tooth disease, and Krabbe's disease; and administering a pharmaceutical composition comprising N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) and derivatives thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers in an amount sufficient to treat the demyelination, wherein the pharmaceutical composition is administered orally, subcutaneously, parenterally, intravenously, peritoneally, or intramuscularly. 2. The method of claim 1, wherein the HEPES is dissolved in sterile water for injection for oral, subcutaneous, parenteral, intravenous, peritoneal, or intramuscular administration. 3. The method of claim 1, wherein the composition is administered once daily on a body weight basis at 10-100 mg/kg. 4. The method of claim 1, wherein the composition treats the one or more demyelination diseases by restoring, repairing, and/or regenerating a myelin sheath.

Details for Patent 9,867,820

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2029-09-17